Cannabis products are rapidly changing. The THC level or ‘strength’ of cannabis flower has increased, particularly in North American markets. Cannabis products have also diversified towards more ‘processed’ forms, including vaping liquids, oral liquids, edibles and beverages, and a wider range of solid concentrates. At the same time, the use of non-THC ‘CBD’ products has increased, particularly among consumers using cannabis products for therapeutic reasons.
Our research is examining changes in product forms and patterns of use, including potential implications for problematic cannabis use. Our work is also helping to develop the methods for assessing different product forms in population-based surveys and self-reported measures.
Recent papers on cannabis products
Use of cannabidiol products in Canada, United States, Australia, Aotearoa New Zealand, United Kingdom and Germany: products, sources and reasons for use.
Wadsworth E, Graham M, Rychert M, Krowartz E, Pacula RL, Hoch E, Freeman T, Hammond D. International Journal of Drug Policy 2026; Sep 19;157(Pt A):105506.
Awareness and use of Delta-8-THC cannabis products in the United States: Findings from national surveys in 2021 and 2022.
Schauer G, Iraniparast M, Hammond D. Cannabis and Cannabinoid Research 2026; In Press.
Prevalence and patterns of different types of non-cigarette tobacco use in England: a population study.
Jackson SE, Taylor E, Tattan-Birch H, East K, Shahad L, Cox S, Mishu MP, Hammond D, Brown J. Nicotine & Tobacco Research 2026; Jun 5:ntag130..
Harm perceptions of smoking versus vaping cannabis and correlates: National surveys of youth and young adults in England, Canada, and the US.
Nottage M, Brose L, Robson D, Hackworth E, Reid JL, Hammond D, East K. Addictive Behaviors 2026; 182:108785.
Exploring THC labelling preferences to communicate the strength of cannabis products: Insights from U.S. consumers.
Dawson D, Hall W, Goodwin I, Carlini BH, Lubman DI, Freeman T, Lorenzetti V, Hammond D. International Journal of Drug Policy 2025; Dec 23;147:105076.
Product characteristics, warnings, and marketing appeals conveyed on Delta-8 THC product packaging in the US and Canada.
Robichaud MO, Spillane TE, Kennedy RD, Hammond D. Journal of Studies on Alcohol and Drugs 2025; Aug 8. doi: 10.15288/jsad.25-00034.
Self-reported cannabis prices and expenditures from legal and illegal sources five years after legalization of non-medical cannabis in Canada.
Rundle S, Hong D, Iraniparast M, Rynard V, Wadsworth E, Pacula RL, Kilmer B, Hammond D. Drug & Alcohol Review 2025; Aug 4. doi: 10.1111/dar.70009.
Cannabis consumer patterns, adverse events, and cannabis risk beliefs: a latent profile analysis in WA State.
Garret SB, Williams J, Carlini BH, Hammond D. Drug & Alcohol Dependence 2025; 273:112728.
Cannabidiol-only product use in Pregnancy in the United States and Canada: Findings from the International Cannabis Policy Study.
Bhatia D, Sakai J, Reddy S, Mikulich S, Hammond D. Obstetrics & Gynecology 2024; 144(2):156-159.
Adverse outcomes of cannabis use in Canada, before and after legalization of non-medical cannabis: cross-sectional analysis of the international cannabis policy study.
Marquette A, Iraniparast M, Hammond D. British Medical Journal Open 2024; 14(1):e077908.
